Literature DB >> 25687023

Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs.

H Iwase1, B Ekser2, V Satyananda1, H Zhou3, H Hara1, P Bajona1, M Wijkstrom1, J K Bhama4, C Long1, M Veroux5, Y Wang6, Y Dai7, C Phelps7, D Ayares7, M B Ezzelarab1, D K C Cooper8.   

Abstract

BACKGROUND: In the pig-to-nonimmunosuppressed baboon artery patch model, a graft from an α1,3-galactosyltransferase gene-knockout pig transgenic for human CD46 (GTKO/CD46) induces a significant adaptive immune response (elicited anti-pig antibody response, increase in T cell proliferation on MLR, cellular infiltration of the graft), which is effectively prevented by anti-CD154mAb-based therapy.
METHODS: As anti-CD154mAb is currently not clinically applicable, we evaluated whether it could be replaced by CD28/B7 pathway blockade or by blockade of both pathways (using belatacept + anti-CD40mAb [2C10R4]). We further investigated whether a patch from a GTKO/CD46 pig with a mutant human MHC class II transactivator (CIITA-DN) gene would allow reduction in the immunosuppressive therapy administered.
RESULTS: When grafts from GTKO/CD46 pigs were transplanted with blockade of both pathways, a minimal or insignificant adaptive response was documented. When a GTKO/CD46/CIITA-DN graft was transplanted, but no immunosuppressive therapy was administered, a marked adaptive response was documented. In the presence of CD28/B7 pathway blockade (abatacept or belatacept), there was a weak adaptive response that was diminished when compared with that to a GTKO/CD46 graft. Blockade of both pathways prevented an adaptive response.
CONCLUSION: Although expression of the mutant MHC CIITA-DN gene was associated with a reduced adaptive immune response when immunosuppressive therapy was inadequate, when blockade of both the CD40/CD154 and CD28/B7 pathways was present, the response even to a GTKO/CD46 graft was suppressed. This was confirmed after GTKO/CD46 heart transplantation in baboons.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-CD40 monoclonal antibody; Artery patch; CTLA4-Ig; Costimulation blockade; Pig; Xenotransplantation

Mesh:

Substances:

Year:  2015        PMID: 25687023      PMCID: PMC4368496          DOI: 10.1016/j.trim.2015.02.003

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  66 in total

1.  Results of gal-knockout porcine thymokidney xenografts.

Authors:  A D Griesemer; A Hirakata; A Shimizu; S Moran; A Tena; H Iwaki; Y Ishikawa; P Schule; J S Arn; S C Robson; J A Fishman; M Sykes; D H Sachs; K Yamada
Journal:  Am J Transplant       Date:  2009-10-21       Impact factor: 8.086

2.  Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates.

Authors:  I R Badell; P W Thompson; A P Turner; M C Russell; J G Avila; J A Cano; J M Robertson; F V Leopardi; E A Strobert; N N Iwakoshi; K A Reimann; M L Ford; A D Kirk; C P Larsen
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

3.  Relative efficiency of porcine and human cytotoxic T-lymphocyte antigen 4 immunoglobulin in inhibiting human CD4+ T-cell responses co-stimulated by porcine and human B7 molecules.

Authors:  Tadatsura Koshika; Carol Phelps; Jason Fang; Seung Eun Lee; Minoru Fujita; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

4.  Initial in vitro investigation of the human immune response to corneal cells from genetically engineered pigs.

Authors:  Hidetaka Hara; Naoko Koike; Cassandra Long; Jordan Piluek; Danny S Roh; Nirmala SundarRaj; James L Funderburgh; Yoshiaki Mizuguchi; Kumiko Isse; Carol J Phelps; Suyapa F Ball; David L Ayares; David K C Cooper
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-15       Impact factor: 4.799

5.  A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Authors:  F Vincenti; B Charpentier; Y Vanrenterghem; L Rostaing; B Bresnahan; P Darji; P Massari; G A Mondragon-Ramirez; M Agarwal; G Di Russo; C-S Lin; P Garg; C P Larsen
Journal:  Am J Transplant       Date:  2010-03       Impact factor: 8.086

6.  A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy.

Authors:  T Aoyagi; K Yamashita; T Suzuki; M Uno; R Goto; M Taniguchi; T Shimamura; N Takahashi; T Miura; K Okimura; T Itoh; A Shimizu; H Furukawa; S Todo
Journal:  Am J Transplant       Date:  2009-06-10       Impact factor: 8.086

7.  Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets.

Authors:  D J van der Windt; R Bottino; A Casu; N Campanile; C Smetanka; J He; N Murase; H Hara; S Ball; B E Loveland; D Ayares; F G Lakkis; D K C Cooper; M Trucco
Journal:  Am J Transplant       Date:  2009-10-21       Impact factor: 8.086

Review 8.  Translating costimulation blockade to the clinic: lessons learned from three pathways.

Authors:  Mandy L Ford; Christian P Larsen
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  Production and characterization of transgenic pigs expressing porcine CTLA4-Ig.

Authors:  Carol J Phelps; Suyapa F Ball; Todd D Vaught; Amy M Vance; Michael Mendicino; Jeffrey A Monahan; Anneke H Walters; Kevin D Wells; Amy S Dandro; Jagdeece J Ramsoondar; David K C Cooper; David L Ayares
Journal:  Xenotransplantation       Date:  2009 Nov-Dec       Impact factor: 3.907

10.  The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients.

Authors:  Mohamed Ezzelarab; Bertha Garcia; Agnes Azimzadeh; Hongtao Sun; Chih Che Lin; Hidetaka Hara; Sean Kelishadi; Tianshu Zhang; Yih Jyh Lin; Hao-Chi Tai; Robert Wagner; Jnanesh Thacker; Noriko Murase; Kenneth McCurry; Rolf N Barth; David Ayares; Richard N Pierson; David K C Cooper
Journal:  Transplantation       Date:  2009-03-27       Impact factor: 4.939

View more
  26 in total

1.  Effect of Rho-kinase Inhibitor, Y27632, on Porcine Corneal Endothelial Cell Culture, Inflammation and Immune Regulation.

Authors:  Whayoung Lee; Yuko Miyagawa; Cassandra Long; Matthew Zhang; David K C Cooper; Hidetaka Hara
Journal:  Ocul Immunol Inflamm       Date:  2015-10-16       Impact factor: 3.070

2.  An Investigation of Extracellular Histones in Pig-To-Baboon Organ Xenotransplantation.

Authors:  Tao Li; Whayoung Lee; Hidetaka Hara; Cassandra Long; Mohamed Ezzelarab; David Ayares; Hai Huang; Yi Wang; Charles T Esmon; David K C Cooper; Hayato Iwase
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

3.  Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Jay Bhama; Hidetaka Hara; Mohamed Ezzelarab; Edwin Klein; Robert Wagner; Cassandra Long; Jnanesh Thacker; Jiang Li; Hao Zhou; Maolin Jiang; Santosh Nagaraju; Huidong Zhou; Massimiliano Veroux; Pietro Bajona; Martin Wijkstrom; Yi Wang; Carol Phelps; Nikolai Klymiuk; Eckhard Wolf; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

Review 4.  In Search of the Ideal Valve: Optimizing Genetic Modifications to Prevent Bioprosthetic Degeneration.

Authors:  Benjamin Smood; Hidetaka Hara; David C Cleveland; David K C Cooper
Journal:  Ann Thorac Surg       Date:  2019-03-02       Impact factor: 4.330

Review 5.  A review of pig liver xenotransplantation: Current problems and recent progress.

Authors:  Xuan Zhang; Xiao Li; Zhaoxu Yang; Kaishan Tao; Quancheng Wang; Bin Dai; Shibin Qu; Wei Peng; Hong Zhang; David K C Cooper; Kefeng Dou
Journal:  Xenotransplantation       Date:  2019-02-15       Impact factor: 3.907

6.  Further evidence for sustained systemic inflammation in xenograft recipients (SIXR).

Authors:  Hayato Iwase; Burcin Ekser; Huidong Zhou; Hong Liu; Vikas Satyananda; Rishab Humar; Pooja Humar; Hidetaka Hara; Cassandra Long; Jay K Bhama; Pietro Bajona; Yi Wang; Martin Wijkstrom; David Ayares; Mohamed B Ezzelarab; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-08-21       Impact factor: 3.907

Review 7.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

8.  B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy.

Authors:  Takayuki Yamamoto; Qi Li; Hidetaka Hara; Liaoran Wang; Hongmin Zhou; Juan Li; Devin E Eckhoff; A Joseph Tector; Edwin C Klein; Ray Lovingood; Mohamed Ezzelarab; David Ayares; Yi Wang; David K C Cooper; Hayato Iwase
Journal:  Transpl Immunol       Date:  2018-08-06       Impact factor: 1.708

Review 9.  Progress in Clinical Encapsulated Islet Xenotransplantation.

Authors:  David K C Cooper; Shinichi Matsumoto; Adrian Abalovich; Takeshi Itoh; Nizar I Mourad; Pierre R Gianello; Eckhard Wolf; Emanuele Cozzi
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

10.  Transplantation of hepatocytes from genetically engineered pigs into baboons.

Authors:  Hayato Iwase; Hong Liu; Eva Schmelzer; Mohamed Ezzelarab; Martin Wijkstrom; Hidetaka Hara; Whayoung Lee; Jagjit Singh; Cassandra Long; Eric Lagasse; Jörg C Gerlach; David K C Cooper; Bruno Gridelli
Journal:  Xenotransplantation       Date:  2017-01-28       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.